Insider Buying: Fate Therapeutics Director Buys 16,667 Shares of Stock (FATE)
Fate Therapeutics (NASDAQ:FATE) Director John Mendlein purchased 16,667 shares of Fate Therapeutics stock in a transaction dated Friday, October 4th. The stock was purchased at an average cost of $6.00 per share, with a total value of $100,002.00. Following the purchase, the director now directly owns 156,774 shares of the company’s stock, valued at approximately $940,644. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Fate Therapeutics (NASDAQ:FATE) traded up 24.06% during mid-day trading on Monday, hitting $8.87. 315,331 shares of the company’s stock traded hands. Fate Therapeutics has a 52 week low of $6.31 and a 52 week high of $7.24. The stock’s 50-day moving average is $6.9 and its 200-day moving average is $6.9. The company’s market cap is $169.9 million.
Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.